Oral Tecovirimat for the Treatment of Smallpox | Zendy

Douglas W. Grosenbach | Zendy; Kady M. Honeychurch | Zendy; Eric A. Rose | Zendy; Jarasvech Chinsangaram | Zendy; Annie Frimm | Zendy; Biswajit Maiti | Zendy; Candace Lovejoy | Zendy; Ingrid Meara | Zendy; Paul G. Long | Zendy; Dennis E. Hruby | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Tecovirimat for the Treatment of Smallpox

Author(s) -

Douglas W. Grosenbach,

Kady M. Honeychurch,

Eric A. Rose,

Jarasvech Chinsangaram,

Annie Frimm,

Biswajit Maiti,

Candace Lovejoy,

Ingrid Meara,

Paul G. Long,

Dennis E. Hruby

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1705688

Subject(s) - smallpox , virology , variola virus , medicine , vaccinia , biology , vaccination , biochemistry , gene , recombinant dna

Smallpox was declared eradicated in 1980, but variola virus (VARV), which causes smallpox, still exists. There is no known effective treatment for smallpox; therefore, tecovirimat is being developed as an oral smallpox therapy. Because clinical trials in a context of natural disease are not possible, an alternative developmental path to evaluate efficacy and safety was needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research